Table 3. TP53 mutations in the 155... | American Society of Hematology

Table 3.

TP53 mutations in the 155 patients in the CLL cohort

Patient ID	Sequence change	Protein change	IGVH mutation and IGVH family	Treatment-free survival, mo	Overall survival, mo
29	807ins12	Inframe insertion	99%, VH4-34	20	22
84^*	797G/A	G266Q	93%, VH3-7	14	17
110	536A/T	H179L	90%, VH3-7	88†	88†
124^*	403T/C	C135R	85%, VH3-15	48†	48†
70	739A/T	N247Y	86%, VH2-5	0	50
146	455C/T	P152L	100% VH3-49	56	66

Patient ID	Sequence change	Protein change	IGVH mutation and IGVH family	Treatment-free survival, mo	Overall survival, mo
29	807ins12	Inframe insertion	99%, VH4-34	20	22
84^*	797G/A	G266Q	93%, VH3-7	14	17
110	536A/T	H179L	90%, VH3-7	88†	88†
124^*	403T/C	C135R	85%, VH3-15	48†	48†
70	739A/T	N247Y	86%, VH2-5	0	50
146	455C/T	P152L	100% VH3-49	56	66

Patients with ATM and TP53 mutations

Treatment or death, respectively, has not occurred